Passage Bio CEO Bruce Goldsmith steps down; Chip Cale named interim CEO, Maxine Gowen interim Executive Chair

Passage BIO, Inc.

Bruce Goldsmith ceases as CEO and director May 31, 2022; will serve as non-employee advisor through Sep 1, 2022 at $50k/month.
Goldsmith receives severance: $566,500 lump sum, COBRA for 12 months, pro-rata 2022 bonus, 100,000-share option at $1.86.
Chip Cale (General Counsel) appointed Interim CEO and President; base salary increased $15k/month, 100,000-share option at $1.80 vesting over 12 months.
Maxine Gowen appointed Interim Executive Chair; receives $20k/month and 40,000-share option at $1.80 vesting over 12 months.
May 26, 2022 annual meeting: Gowen and Woiwode re-elected as Class II directors; KPMG ratified as auditor for 2022.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bruce Goldsmith

President and Chief Executive Officer

PASG · Passage BIO, Inc.

Effective: 2022-05-31
Successor: Edgar B. (Chip) Cale
Filed: June 1, 2022, 7:59 PM ET

Dr. Goldsmith ceased his role as the Company’s President and Chief Executive Officer, effective May 31, 2022

Appointed (interim)

Edgar B. (Chip) Cale

Interim Chief Executive Officer and President

PASG · Passage BIO, Inc.

Effective: 2022-05-31
Filed: June 1, 2022, 7:59 PM ET

Effective as of the Transition Date, the Board appointed Edgar B. (Chip) Cale, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Goldsmith as Interim Chief Executive Officer and President.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bruce Goldsmith departed as President and Chief Executive Officer at Passage BIO, Inc..

Action: ceased
Role: President and Chief Executive Officer

Exact text from the filing

Dr. Goldsmith ceased his role as the Company’s President and Chief Executive Officer, effective May 31, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Edgar B. (Chip) Cale was appointed as Interim Chief Executive Officer and President at Passage BIO, Inc..

Action: appointed
Role: Interim Chief Executive Officer and President

Exact text from the filing

Effective as of the Transition Date, the Board appointed Edgar B. (Chip) Cale, the Company’s General Counsel and Corporate Secretary, to succeed Dr. Goldsmith as Interim Chief Executive Officer and President.

View on SEC.gov

Passage BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-066896

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.